-DOCSTART- -X- O
Background. -X- _ O
Intravenous -X- _ B-Intervention
zanamivir -X- _ I-Intervention
is -X- _ O
a -X- _ O
neuraminidase -X- _ O
inhibitor -X- _ O
suitable -X- _ O
for -X- _ O
treatment -X- _ O
of -X- _ O
hospitalized -X- _ B-Patient
patients -X- _ I-Patient
with -X- _ I-Patient
severe -X- _ I-Patient
influenza. -X- _ I-Patient
Methods. -X- _ O
Patients -X- _ O
were -X- _ O
treated -X- _ O
with -X- _ O
intravenous -X- _ B-Intervention
zanamivir -X- _ I-Intervention
600 -X- _ I-Intervention
mg -X- _ I-Intervention
twice -X- _ I-Intervention
daily -X- _ I-Intervention
, -X- _ O
adjusted -X- _ O
for -X- _ O
renal -X- _ O
impairment -X- _ O
, -X- _ O
for -X- _ O
up -X- _ O
to -X- _ O
10 -X- _ O
days. -X- _ O
Primary -X- _ O
outcomes -X- _ O
included -X- _ O
adverse -X- _ O
events -X- _ O
( -X- _ O
AEs -X- _ O
) -X- _ O
, -X- _ O
and -X- _ O
clinical -X- _ O
/ -X- _ O
laboratory -X- _ O
parameters. -X- _ O
Pharmacokinetics -X- _ O
, -X- _ O
viral -X- _ O
load -X- _ O
, -X- _ O
and -X- _ O
disease -X- _ O
course -X- _ O
were -X- _ O
also -X- _ O
assessed. -X- _ O
Results. -X- _ O
One -X- _ B-Outcome
hundred -X- _ I-Outcome
thirty -X- _ I-Outcome
patients -X- _ I-Outcome
received -X- _ I-Outcome
intravenous -X- _ I-Outcome
zanamivir -X- _ I-Outcome
( -X- _ I-Outcome
median -X- _ I-Outcome
, -X- _ I-Outcome
5 -X- _ I-Outcome
days -X- _ I-Outcome
; -X- _ I-Outcome
range -X- _ I-Outcome
, -X- _ I-Outcome
1–11 -X- _ I-Outcome
) -X- _ I-Outcome
a -X- _ I-Outcome
median -X- _ I-Outcome
of -X- _ I-Outcome
4.5 -X- _ I-Outcome
days -X- _ I-Outcome
( -X- _ I-Outcome
range -X- _ I-Outcome
, -X- _ I-Outcome
1–7 -X- _ I-Outcome
) -X- _ I-Outcome
after -X- _ I-Outcome
onset -X- _ I-Outcome
of -X- _ I-Outcome
influenza -X- _ I-Outcome
; -X- _ I-Outcome
83 -X- _ I-Outcome
% -X- _ I-Outcome
required -X- _ I-Outcome
intensive -X- _ I-Outcome
care. -X- _ I-Outcome
The -X- _ I-Outcome
most -X- _ I-Outcome
common -X- _ I-Outcome
influenza -X- _ I-Outcome
type -X- _ I-Outcome
/ -X- _ I-Outcome
subtype -X- _ I-Outcome
was -X- _ I-Outcome
A -X- _ I-Outcome
/ -X- _ I-Outcome
H1N1pdm09 -X- _ I-Outcome
( -X- _ I-Outcome
71 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
AEs -X- _ I-Outcome
and -X- _ I-Outcome
serious -X- _ I-Outcome
AEs -X- _ I-Outcome
were -X- _ I-Outcome
reported -X- _ I-Outcome
in -X- _ I-Outcome
85 -X- _ I-Outcome
% -X- _ I-Outcome
and -X- _ I-Outcome
34 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
patients -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
; -X- _ I-Outcome
serious -X- _ I-Outcome
AEs -X- _ I-Outcome
included -X- _ I-Outcome
bacterial -X- _ I-Outcome
pulmonary -X- _ I-Outcome
infections -X- _ I-Outcome
( -X- _ I-Outcome
8 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
respiratory -X- _ I-Outcome
failure -X- _ I-Outcome
( -X- _ I-Outcome
7 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
sepsis -X- _ I-Outcome
or -X- _ I-Outcome
septic -X- _ I-Outcome
shock -X- _ I-Outcome
( -X- _ I-Outcome
5 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
cardiogenic -X- _ I-Outcome
shock -X- _ I-Outcome
( -X- _ I-Outcome
5 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
No -X- _ I-Outcome
drug-related -X- _ I-Outcome
trends -X- _ I-Outcome
in -X- _ I-Outcome
safety -X- _ I-Outcome
parameters -X- _ I-Outcome
were -X- _ I-Outcome
identified. -X- _ I-Outcome
Protocol-defined -X- _ I-Outcome
liver -X- _ I-Outcome
events -X- _ I-Outcome
were -X- _ I-Outcome
observed -X- _ I-Outcome
in -X- _ I-Outcome
13 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
patients. -X- _ I-Outcome
The -X- _ I-Outcome
14- -X- _ I-Outcome
and -X- _ I-Outcome
28-day -X- _ I-Outcome
all-cause -X- _ I-Outcome
mortality -X- _ I-Outcome
rates -X- _ I-Outcome
were -X- _ I-Outcome
13 -X- _ I-Outcome
% -X- _ I-Outcome
and -X- _ I-Outcome
17 -X- _ I-Outcome
% -X- _ I-Outcome
. -X- _ I-Outcome
No -X- _ I-Outcome
fatalities -X- _ I-Outcome
were -X- _ I-Outcome
considered -X- _ I-Outcome
zanamivir -X- _ I-Outcome
related. -X- _ I-Outcome
Pharmacokinetic -X- _ I-Outcome
data -X- _ I-Outcome
showed -X- _ I-Outcome
dose -X- _ I-Outcome
adjustments -X- _ I-Outcome
for -X- _ I-Outcome
renal -X- _ I-Outcome
impairment -X- _ I-Outcome
yielded -X- _ I-Outcome
similar -X- _ I-Outcome
zanamivir -X- _ I-Outcome
exposures. -X- _ I-Outcome
Ninety-three -X- _ I-Outcome
patients -X- _ I-Outcome
, -X- _ I-Outcome
positive -X- _ I-Outcome
at -X- _ I-Outcome
baseline -X- _ I-Outcome
for -X- _ I-Outcome
influenza -X- _ I-Outcome
by -X- _ I-Outcome
quantitative -X- _ I-Outcome
polymerase -X- _ I-Outcome
chain -X- _ I-Outcome
reaction -X- _ I-Outcome
, -X- _ I-Outcome
showed -X- _ I-Outcome
a -X- _ I-Outcome
median -X- _ I-Outcome
decrease -X- _ I-Outcome
in -X- _ I-Outcome
viral -X- _ I-Outcome
load -X- _ I-Outcome
of -X- _ I-Outcome
1.42 -X- _ I-Outcome
log -X- _ I-Outcome
( -X- _ I-Outcome
10 -X- _ I-Outcome
) -X- _ I-Outcome
copies -X- _ I-Outcome
/ -X- _ I-Outcome
mL -X- _ I-Outcome
after -X- _ I-Outcome
2 -X- _ I-Outcome
days -X- _ I-Outcome
of -X- _ I-Outcome
treatment. -X- _ I-Outcome
Conclusions. -X- _ O
Safety -X- _ O
, -X- _ O
pharmacokinetic -X- _ O
and -X- _ O
clinical -X- _ O
outcome -X- _ O
data -X- _ O
support -X- _ O
further -X- _ O
investigation -X- _ O
of -X- _ O
intravenous -X- _ O
zanamivir. -X- _ O
Clinical -X- _ O
Trials -X- _ O
Registration -X- _ O
NCT01014988 -X- _ O
. -X- _ O

